Alcon has announced positive topline results from two pivotal phase 3 clinical trials (Comet-2 and Comet-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symp
For the first time since the pandemic, Volunteer Ophthalmic Services Overseas’ (VOSO’s) chair Dr Andrew Riley and I made a five-day visit to Nuku'alofa in Tonga in September. A regular volunteer, this
Belgian start-up Azalea Vision has successfully demonstrated its first functional prototype of smart contact lens Alma, designed to offer a non-surgical solution for patients suffering from keratoconu
In the second part of a journey to locations connected with the sea, ‘seastainable’ eyewear brand Sea2see visited Marseille in France. Against the backdrop of the daily work of the fishing ind
Optometry researchers from the University of California, Berkeley, have uncovered highly specialised cells known as direction-selective ganglion cells, which are vital for maintaining sharp and steady images.
Silhouette has entered an exclusive distribution partnership with VMD Eyewear in Australia. Thanking previous partner Mimo for its longstanding collaboration, Silhouette said the deal extends t
Strolling through the streets of Los Angeles with wife Jennifer Lopez, Ben Affleck was recently spotted wearing Blackfin sunglasses. Affleck chose Blackfin's Eagle Head model, crafted from ultra-light
Almost 3% of 70-year-olds in a Swedish study were unaware they had glaucoma.
That’s a wrap! The New Zealand Optometry Student Society (NZOSS) finished 2023 with a record-breaking 19 events, a first-time international collaboration with Optometry Australia and Australian univer
US actor Brad Pitt was recently spotted wearing Etnia Barcelona's classic sun model Regencos. The 100% recyclable pure mineral lenses feature high definition colour technology, anti-scratch, anti-glar
As ever, RANZCO’s poster area offered a glimpse into some of the work behind the scenes by the region’s ophthalmologists and clinical researchers, and included a healthy smattering from Aotearoa. Here are some that caught our eye.
The results of a 48-week trial of MCO-010, an intravitreal, adeno-associated virus (AAV2)-delivered optogenetic therapy, on Stargardt disease patients, showed significant improvements in visual acuity and reported no serious adverse effects, reported researchers from Nanoscope Therapeutics.